The cold-adapted (ca) mutant of the A/Ann Arbor/6/60 (H2N2) strain of influenza A virus is adapted to grow efficiently at 25°C and has a temperature-sensitive phenotype that restricts its growth at 37°C (2) . Reassortment of this virus with wild-type (wt) influenza A viruses allows the selection of reassortant viruses that contain the hemagglutinin (HA) and neuraminidase (NA) gene segments of the wt parent virus and the other six genome segments of the ca parent virus. Convincing documentation suggests that such reassortant viruses are attenuated in animals and humans (3, 5, 6) . Clinical studies have demonstrated that the ca reassortant viruses are safe and effectively induce immunity against influenza virus when they are administered by the intranasal route (4) .
In addition to their immunizing effects, the ca reassortant viruses act as dominant-negative mutants; i.e., in mixed infections of cell cultures or embryonated eggs, they directly interfere with the growth of pathogenic influenza A viruses (8, 10 ; unpublished data). Experiments in cell culture have demonstrated that this interference occurs at the level of gene expression and that in mixed infections the viral proteins synthesized are predominantly those of the ca virus. Coldadapted reassortant viruses are dominant over wt viruses, which bear completely unrelated transmembrane glycoproteins, indicating that the dominance is independent of the HA and NA genes (8) . Several lines of evidence, including the use of single-gene reassortants, show that gene segment 7, encoding the Ml and M2 proteins, plays a primary role in the dominance phenotype of the ca virus (11) .
Most recently, it has been found that the ca reassortant virus suppresses clinical disease in ferrets when given simultaneously with a virulent influenza A virus (9) . The ca virus effectively prevents disease even when the virulent virus is of a different subtype than the ca virus, confirming the irrelevance of the transmembrane glycoproteins to the dominance phenotype. Interestingly, ferrets produce antibodies to both subtypes under these circumstances in the absence of clinical disease. These findings suggest the possibility of the development of a novel class of antiviral agents for influenza, namely, a live, dominant-negative, attenuated mutant virus that interferes with the replication of epidemic strains of virus. The current report describes a randomized, double-blind study which assessed the ability of ca influenza virus to modify disease caused by a homologous wt influenza A virus when both viruses were administered simultaneously to seronegative human volunteers. Virus isolation. Nasal washes for virus isolation were obtained prior to inoculation and daily for 7 days after virus isolation. The nares were washed with 10 ml of Ringer's lactate, and the washing returns were mixed with 5 x VIB to a final concentration of 1 x VIB and were transported to the laboratory on wet ice. Samples were immediately inoculated on Madin-Darby canine kidney (MDCK) cells and were incubated at 33°C, while the remainder was frozen in aliquots at -70°C. The level of wt virus replication was then determined by plaque assay of a fresh aliquot of each sample exhibiting a viral cytopathic effect as well as of the sample from the day prior to and the day after such samples were obtained. This assay was carried out on MDCK cells at 38.5°C by using an overlay of 0.6% agarose-L-15 nutrient medium. In preliminary experiments it was determined that incubation at this temperature produces a greater than 10,000-fold reduction in the level of replication of the ca virus, with no significant effect on the replication of the wt virus (data not shown). Each titration was performed twice on fresh aliquots, and the higher of the two titrations was taken as the PFU per milliliter value. In a subset of samples, plaque assays of nasal washes were also carried out at 34°C to evaluate the presence of reassortant viruses (see below). Sera obtained prechallenge and 3 weeks postchallenge were tested for the level of antibody to the challenge virus by HI by using the ca A/Kawasaki/86 virus as antigen.
MATERUILS AND METHODS

Subjects
Studies of the ca A/Kawasaki/86 virus. The results for subjects who received wt virus alone or a mixture of wt and ca viruses in the inpatient challenge studies described above were compared with the results for subjects who received the ca A/Kawasaki/86 virus alone (lot E-271; PRI/DynCorp) as outpatients during the period of time that the inpatient challenge studies were performed. A total of 14 3 to 7 after virus inoculation and were handled as described above for the challenge studies.
Analysis of viral proteins. Monolayer cultures of MDCK cells in 96-well trays were inoculated with agar plugs from well-separated virus plaques and were incubated at 34°C. The monolayers were examined by light microscopy and were radiolabeled with [35S]methionine for 2 h at the first sign of virus-induced cytopathology, usually between 24 and 48 h after the addition of the agar plug to the well. A cell lysate was prepared and the viral proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as described previously (8) .
RESULTS
Clinical responses to virus challenge. Individual symptom scores by day for the subjects in the three challenge groups are plotted in Fig. 1 . The patterns of symptoms in the group given the mixed inoculum of wt plus ca viruses suggest that clinical disease was milder in those individuals than in the group given the wt virus alone. The individual symptom scores for volunteers who received the wt virus alone reached severity levels not seen for the other groups of subjects. In addition, the pattern of symptom scores for the group given the mixed inoculum was quite similar to that for the group given only the ca virus, suggesting that the level of symptoms in the mixed inoculum group was only slightly above that expected for the group given the ca virus alone. It is of interest that the difference in the pattern of symptom scores could be detected in both the challenge experiment performed in May 1991 and the second challenge performed in October 1991. The difference in mean peak symptom score between those receiving wt virus alone (6.5 ± 1.9) and those receiving wt and ca viruses simultaneously (4.2 ± 0.8) did not achieve statistical significance (P = 0.27; two-tailed t test) ( Table 1) . However, the difference in the mean peak symptom scores between those receiving wt virus alone and those receiving ca virus alone (2.6 0.2) also was not statistically significant in this small study (P = 0.07). The incidence of fever, defined by a temperature of greater than 38.0°C, was similar in those who received the wt virus alone (three subjects) and those who received the mixed inoculum of wt and ca viruses (two subjects). However, the fevers that were observed were higher in those who received the wt virus alone ( Table 1) . None of the subjects in the group given the ca virus alone showed a febrile response.
Virologic and serologic responses. The geometric mean prechallenge HI titers in the sera of the subjects in the three challenge groups were similar. All of the volunteers given wt virus alone, 12 of 13 volunteers in the group given wt and ca viruses, and 9 of 14 volunteers given ca virus alone had a fourfold rise in antibody titer following challenge ( Table 2 ). The replication of wt virus in the respiratory tract was assessed by determining the titer of virus in nasal secretions at 38.5°C, a temperature at which the replication of the ca virus is restricted by more than 10,000-fold. In the group receiving wt virus alone, plaque-forming viruses were recovered at 38.5°C from at least one sample from 10 of 14 subjects (71.4%), and in the group given the mixed inoculum of wt and ca viruses, plaque-forming viruses were recovered from 8 of 13 subjects (61.5%). There was no significant difference in the mean peak titer of virus shed by the two groups (Table 2 ). However, there was some difference in the pattern of virus shedding, as shown in Fig. 2 . In subjects given the wt virus alone, peak virus titers were recorded 2 days after infection, while in the group given the mixed inoculum, the peak of virus shedding was delayed until day 4 after infection. It must be pointed out that a delayed pattern of virus shedding in the mixed inoculum group was 4 .0 days and I036 TCID50s/ml, rcspectively) (7). In the present study, the mean titer of virus in the volunteers given ca virus alone was 10'" TCID50s/ml. Under these conditions it would be unlikely that the ca virus could be detected by the endpoint dilution methods used in the present study unless its growth had been significantly rescued by coinfection with the wt virus.
Further clonal analysis was carried out on nasal washings obtained from five volunteers given the mixed inoculum of wt and ca viruses. The virus-positive specimens tested were taken on different days (days 2 to 6) after infection. Single clones obtained at the permissive temperature (34°C) were randomly selected and furthcr amplified at 34°C in MDCK cells in 96-well trays. The cells were labeled after infection with
[35S]methionine, and the proteins were analyzed by SDS-PAGE. Under these conditions, the PA, NP, Ml, and NS1 proteins of the ca reassortant A/Kawasaki/86 virus (these proteins were derived from the A/Ann Arbor/6/60 virus) can be distinguished from those of the wt A/Kawasaki/86 virus (8) . These migration differences were used to detect the presence of reassortants in the viruses recovered from the nasal washings of the volunteers given the mixed inoculum of wt and ca viruses.
A total of 340 virus clones were isolated from the nasal washings, and 8 of these (2.4Cc) were identified as reassortants by analysis of the migration of their proteins. Of the eight reassortants, seven were apparent single-genc reassortants, five of which derived the M genc segment from the ca virus and two Studies demonstrating the ability of the attenuated ca virus to interfere with epidemic strains of influenza A virus in animals have suggested a potentially expanided prophylactic use of ca virus vaccine (8, 9, 10) . This potential is particularly pertinent in the case of influenza since the incubation period of this disease is short (I to 2 days) in comparison with the time required for the vaccine to induce immunity (I to 2 weeks (9) ? Since the antigenic subtypes of influenza A virus are irrelevant to the dominance phenotype (8, 9) , the attenuated virus might offer short-term protection in the event of an antigenic "shift" and the appearance of a new influenza strain for which there is no available vaccine.
It seems evident that the dominance phenotype is a desirable characteristic for any live virus vaccine. In addition to offering protection against any wt revertants that might arise during the vaccination process, the dominance phenotype may provide short-term protection against any natural exposure to an epidemic virus that occurs before an effective antibody response is mounted. More complete evaluation of the clinical usefulness of this effect will require further studies under field conditions.
